EP4739656A1 - Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique - Google Patents

Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique

Info

Publication number
EP4739656A1
EP4739656A1 EP24742983.0A EP24742983A EP4739656A1 EP 4739656 A1 EP4739656 A1 EP 4739656A1 EP 24742983 A EP24742983 A EP 24742983A EP 4739656 A1 EP4739656 A1 EP 4739656A1
Authority
EP
European Patent Office
Prior art keywords
piperidin
piperidine
sulfonamide
chlorophenoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24742983.0A
Other languages
German (de)
English (en)
Inventor
Marko Ahlmark
Anssi Haikarainen
Ari-Pekka Koivisto
Esa KUMPULAINEN
Aleksi SAHARI
Ainoleena TURKU
Emilia VÄISÄNEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of EP4739656A1 publication Critical patent/EP4739656A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne des composés de formule I, dans laquelle X et R1-R4, n et m ont la signification donnée dans la description, et des sels pharmaceutiquement acceptables de ceux-ci. Les composés de formule I présentent une activité antagoniste de GPR183 et sont donc utiles dans le traitement ou la prévention d'un trouble, d'un état ou d'une maladie où l'antagoniste de GRP183 est indiqué comme étant utile, tel que par ex., la douleur chronique, par ex., l'arthrose, la lombalgie chronique, la douleur neuropathique et des maladies du système immunitaire, par ex., les maladies inflammatoires chroniques de l'intestin, par ex., la colite et la maladie de Crohn, la sclérose en plaques, la polyarthrite rhumatoïde, les maladies pulmonaires inflammatoires, par ex., l'asthme et le psoriasis.
EP24742983.0A 2023-07-05 2024-07-04 Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique Pending EP4739656A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20237131 2023-07-05
PCT/FI2024/050372 WO2025008574A1 (fr) 2023-07-05 2024-07-04 Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique

Publications (1)

Publication Number Publication Date
EP4739656A1 true EP4739656A1 (fr) 2026-05-13

Family

ID=91950461

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24742983.0A Pending EP4739656A1 (fr) 2023-07-05 2024-07-04 Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique

Country Status (11)

Country Link
EP (1) EP4739656A1 (fr)
KR (1) KR20260035942A (fr)
CN (1) CN121794256A (fr)
AR (1) AR133165A1 (fr)
AU (1) AU2024290016A1 (fr)
CO (1) CO2026000808A2 (fr)
IL (1) IL325730A (fr)
MX (1) MX2025015183A (fr)
PE (1) PE20260501A1 (fr)
TW (1) TW202517611A (fr)
WO (1) WO2025008574A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948597A1 (fr) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derives modulant des canaux ioniques
WO2015048570A2 (fr) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Modulateurs ebi2
US11919895B2 (en) 2019-10-25 2024-03-05 Saint Louis University GPR183 antagonists for the treatment of pain
MX2024004722A (es) 2021-10-18 2024-07-24 Nanjing Immunophage Biotech Co Ltd Compuestos y sus usos como inhibidores de gpr183.

Also Published As

Publication number Publication date
AR133165A1 (es) 2025-09-03
TW202517611A (zh) 2025-05-01
CN121794256A (zh) 2026-04-03
MX2025015183A (es) 2026-02-03
KR20260035942A (ko) 2026-03-13
IL325730A (en) 2026-03-01
AU2024290016A1 (en) 2026-02-19
CO2026000808A2 (es) 2026-02-13
PE20260501A1 (es) 2026-02-27
WO2025008574A1 (fr) 2025-01-09

Similar Documents

Publication Publication Date Title
CN103429585B (zh) 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物
US7456164B2 (en) 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
ES2337376T3 (es) Agentes receptores de la histamina h3, preparacion y usos terapeuticos.
EP4635568A2 (fr) Composés, sels de ceux-ci et procédés de traitement de maladies
KR20140107551A (ko) RORc 조절제로서의 벤질 설폰아마이드 유도체
CA2565843A1 (fr) Nouveaux composes de derives de proline et de morpholine
WO2019040106A2 (fr) Composés, sels associés et méthodes pour le traitement de maladies
TW200303304A (en) Chemical compounds
CA2957048A1 (fr) Derives de pyrimidine substitues par un heterocyclyle eventuellement condenses utiles pour le traitement des maladies inflammatoires, metaboliques, oncologiques et auto-immunes
EA011161B1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве h-лигандов
AU2008227301A1 (en) Novel benzamide derivatives and process for the preparation thereof
WO2021113368A1 (fr) Antagonistes de sstr5
WO2008100621A2 (fr) Modulateurs de la cathepsine s au thioéther de tétrahydro-pyrazolo-pyridine
EP3092239A1 (fr) Dérivés d'aryle sultame utilisés en tant que modulateurs de rorc
WO2019040105A2 (fr) Composés, sels de ces composés et procédés pour le traitement de maladies
AU2018372752B2 (en) Pyrimidine sulfamide derivative and preparation method and medical application thereof
CA3090788A1 (fr) Antagonistes heterocycliques du recepteur p2y14
ES2335305T3 (es) Derivados de pirrolidina como antagonistas del receptor h3 de histamina.
WO2025008574A1 (fr) Dérivés de 2-phénoxy-1-(4-(alkylsulfonyl)pipéridin-1-yl)éthan-1-one et 3-phényl-1-(4-(alkylsulfonyl)pipéridin-1-yl)prop-2-én-1-one utilisés en tant qu'agonistes gpr183 pour le traitement de la douleur chronique
US11440884B2 (en) Compounds, salts thereof and methods for treatment of diseases
CA2751239C (fr) Azetidines en tant qu'antagonistes des recepteurs h3 de l'histamine
CN105899506A (zh) 作为RORc调节剂的杂芳基磺内酰胺衍生物
WO2024220453A1 (fr) Agonistes de pyrrolidinone urée fpr2
EP4434522A2 (fr) Antagonistes hétérocycliques du récepteur p2y14

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR